หน้าแรก
ค้นหา
Dr. Matulonis Discusses Maintenance in Ovarian Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Matulonis Discusses Maintenance in Ovarian Cancer
Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer
Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer
Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer
Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer
Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer
Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
Ursula A. Matulonis, MD, on gynecologic cancer treatment | Dana-Farber Cancer Institute
Maintenance Therapy in Ovarian Cancer: PARP Inhibitors
Niraparib Maintenance Therapy in Ovarian Cancer
Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian Cancer
Ovarian Cancer Decisions: Treatment Versus Maintenance
Combination therapy to treat ovarian cancer: promising results from the ANANOVA trial
Managing Ovarian Cancer Patients in the Future
What is Ovarian Cancer? | Dana-Farber Cancer Institute
Looking forward to ASCO: updates in ovarian cancer
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian Cancer
Sequencing Therapies in Ovarian Cancer
About Ovarian Cancer
